BK do you really think that is viable that the company can present Kevetrin again as a work in progress because of a protocol change late in the trial? Mind you its also an upgrade from poster to presentation. Also we were initially informed/hinted of this in the same PR that presented the disappearing spleen lesion.
Dr. Sharpario is a big fish at ASCO is it possible that he got us in under the "holy shxx" category?
News 
Market Data 
Discover 
AI
